172 related articles for article (PubMed ID: 33200227)
1. A randomized phase III trial of personalized peptide vaccination for castration‑resistant prostate cancer progressing after docetaxel.
Noguchi M; Fujimoto K; Arai G; Uemura H; Hashine K; Matsumoto H; Fukasawa S; Kohjimoto Y; Nakatsu H; Takenaka A; Fujisawa M; Uemura H; Naito S; Egawa S; Fujimoto H; Hinotsu S; Itoh K
Oncol Rep; 2021 Jan; 45(1):159-168. PubMed ID: 33200227
[TBL] [Abstract][Full Text] [Related]
2. A Phase 2 Randomized Controlled Trial of Personalized Peptide Vaccine Immunotherapy with Low-dose Dexamethasone Versus Dexamethasone Alone in Chemotherapy-naive Castration-resistant Prostate Cancer.
Yoshimura K; Minami T; Nozawa M; Kimura T; Egawa S; Fujimoto H; Yamada A; Itoh K; Uemura H
Eur Urol; 2016 Jul; 70(1):35-41. PubMed ID: 26782346
[TBL] [Abstract][Full Text] [Related]
3. Mixed 20-peptide cancer vaccine in combination with docetaxel and dexamethasone for castration-resistant prostate cancer: a randomized phase II trial.
Noguchi M; Arai G; Egawa S; Ohyama C; Naito S; Matsumoto K; Uemura H; Nakagawa M; Nasu Y; Eto M; Suekane S; Sasada T; Shichijo S; Yamada A; Kakuma T; Itoh K
Cancer Immunol Immunother; 2020 May; 69(5):847-857. PubMed ID: 32025848
[TBL] [Abstract][Full Text] [Related]
4. A randomized, double-blind, phase III trial of personalized peptide vaccination for recurrent glioblastoma.
Narita Y; Arakawa Y; Yamasaki F; Nishikawa R; Aoki T; Kanamori M; Nagane M; Kumabe T; Hirose Y; Ichikawa T; Kobayashi H; Fujimaki T; Goto H; Takeshima H; Ueba T; Abe H; Tamiya T; Sonoda Y; Natsume A; Kakuma T; Sugita Y; Komatsu N; Yamada A; Sasada T; Matsueda S; Shichijo S; Itoh K; Terasaki M
Neuro Oncol; 2019 Feb; 21(3):348-359. PubMed ID: 30500939
[TBL] [Abstract][Full Text] [Related]
5. A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time.
Noguchi M; Moriya F; Suekane S; Ohnishi R; Matsueda S; Sasada T; Yamada A; Itoh K
BMC Cancer; 2013 Dec; 13():613. PubMed ID: 24373380
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of personalized peptide vaccination for castration-resistant prostate cancer patients who failed in docetaxel-based chemotherapy.
Noguchi M; Moriya F; Suekane S; Matsuoka K; Arai G; Matsueda S; Sasada T; Yamada A; Itoh K
Prostate; 2012 Jun; 72(8):834-45. PubMed ID: 21932426
[TBL] [Abstract][Full Text] [Related]
7. Phase I clinical trial of cell division associated 1 (CDCA1) peptide vaccination for castration resistant prostate cancer.
Obara W; Sato F; Takeda K; Kato R; Kato Y; Kanehira M; Takata R; Mimata H; Sugai T; Nakamura Y; Fujioka T
Cancer Sci; 2017 Jul; 108(7):1452-1457. PubMed ID: 28498618
[TBL] [Abstract][Full Text] [Related]
8. A randomized phase II clinical trial of personalized peptide vaccination with metronomic low-dose cyclophosphamide in patients with metastatic castration-resistant prostate cancer.
Noguchi M; Moriya F; Koga N; Matsueda S; Sasada T; Yamada A; Kakuma T; Itoh K
Cancer Immunol Immunother; 2016 Feb; 65(2):151-60. PubMed ID: 26728480
[TBL] [Abstract][Full Text] [Related]
9. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
[TBL] [Abstract][Full Text] [Related]
10. An Open-Label, Randomized Phase II Trial of Personalized Peptide Vaccination in Patients with Bladder Cancer that Progressed after Platinum-Based Chemotherapy.
Noguchi M; Matsumoto K; Uemura H; Arai G; Eto M; Naito S; Ohyama C; Nasu Y; Tanaka M; Moriya F; Suekane S; Matsueda S; Komatsu N; Sasada T; Yamada A; Kakuma T; Itoh K
Clin Cancer Res; 2016 Jan; 22(1):54-60. PubMed ID: 26581246
[TBL] [Abstract][Full Text] [Related]
11. Randomized Phase II Study of Docetaxel plus Personalized Peptide Vaccination versus Docetaxel plus Placebo for Patients with Previously Treated Advanced Wild Type EGFR Non-Small-Cell Lung Cancer.
Takayama K; Sugawara S; Saijo Y; Maemondo M; Sato A; Takamori S; Harada T; Sasada T; Kakuma T; Kishimoto J; Yamada A; Noguchi M; Itoh K; Nakanishi Y
J Immunol Res; 2016; 2016():1745108. PubMed ID: 27274999
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy.
Mulders PF; Molina A; Marberger M; Saad F; Higano CS; Chi KN; Li J; Kheoh T; Haqq CM; Fizazi K
Eur Urol; 2014 May; 65(5):875-83. PubMed ID: 24099659
[TBL] [Abstract][Full Text] [Related]
13. Commentary on: "Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): A multicentre, randomised, double-blind, phase 3 trial." Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, Krainer M, Houede N, Santos R, Mahammedi H, Ng S, Maio M, Franke FA, Sundar S, Agarwal N, Bergman AM, Ciuleanu TE, Korbenfeld E, Sengeløv L, Hansen S, Logothetis C, Beer TM, McHenry MB, Gagnier P, Liu D, Gerritsen WR, CA184-043 Investigators. Departments of Urology and Immunology and Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Rochester, MN, USA, Electronic address: kwon.eugene@mayo.edu; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center and Brady Urological Institute, Baltimore, MD, USA; Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA; Institut Gustave Roussy, University of Paris-Sud, Villejuif, France; Institut Gustave Roussy, Villejuif, France; VU University Medical Centre, Amsterdam, Netherlands; Vienna General Hospital, Medical University Vienna, Vienna, Austria; Institut Bergonié, Bordeaux, France; CHU Caremeau, Nimes, France; Centro Médico Austral, Buenos Aires, Argentina; Centre Jean Perrin, Clermont-Ferrand, France; St John of God Hospital, Subiaco, WA, Australia; University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy; Hospital de Caridade de Ijuí, Ijuí, Brazil; Nottingham University Hospital, Nottingham, UK; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA; Netherlands Cancer Institute and Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; Institute of Oncology Ion Chiricuta and University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania; Hospital Británico de Buenos Aires, Buenos Aires, Argentina; Herlev Hospital, Herlev, Denmark; Odense University Hospital, Odense, Denmark; University of Texas MD Anderson Cancer Center, Houston,
Trump D
Urol Oncol; 2016 May; 34(5):249-50. PubMed ID: 25907621
[TBL] [Abstract][Full Text] [Related]
14. Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer.
Sternberg C; Armstrong A; Pili R; Ng S; Huddart R; Agarwal N; Khvorostenko D; Lyulko O; Brize A; Vogelzang N; Delva R; Harza M; Thanos A; James N; Werbrouck P; Bögemann M; Hutson T; Milecki P; Chowdhury S; Gallardo E; Schwartsmann G; Pouget JC; Baton F; Nederman T; Tuvesson H; Carducci M
J Clin Oncol; 2016 Aug; 34(22):2636-43. PubMed ID: 27298414
[TBL] [Abstract][Full Text] [Related]
15. Multicenter randomized phase II study comparing docetaxel plus curcumin versus docetaxel plus placebo in first-line treatment of metastatic castration-resistant prostate cancer.
Passildas-Jahanmohan J; Eymard JC; Pouget M; Kwiatkowski F; Van Praagh I; Savareux L; Atger M; Durando X; Abrial C; Richard D; Ginzac Couvé A; Thivat E; Monange B; Chollet P; Mahammedi H
Cancer Med; 2021 Apr; 10(7):2332-2340. PubMed ID: 33666378
[TBL] [Abstract][Full Text] [Related]
16. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
[TBL] [Abstract][Full Text] [Related]
17. Identification of biomarkers for personalized peptide vaccination in 2,588 cancer patients.
Suekane S; Yutani S; Yamada A; Sasada T; Matsueda S; Takamori S; Toh U; Kawano K; Yoshiyama K; Sakamoto S; Sugawara S; Komatsu N; Yamada T; Naito M; Terasaki M; Mine T; Itoh K; Shichijo S; Noguchi M
Int J Oncol; 2020 Jun; 56(6):1479-1489. PubMed ID: 32236612
[TBL] [Abstract][Full Text] [Related]
18. PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: Multicenter validation in patients from the Chinese Prostate Cancer Consortium.
Pei X; Wu K; Sun Y; Gao X; Gou X; Xu J; Gao F; He D; Li L;
Urol Oncol; 2020 Jan; 38(1):2.e11-2.e17. PubMed ID: 31672485
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and toxicity of cabazitaxel for treatment of docetaxel-resistant prostate cancer correlating with the initial doses in Japanese patients.
Terada N; Kamoto T; Tsukino H; Mukai S; Akamatsu S; Inoue T; Ogawa O; Narita S; Habuchi T; Yamashita S; Mitsuzuka K; Arai Y; Kandori S; Kojima T; Nishiyama H; Kawamura Y; Shimizu Y; Terachi T; Sugi M; Kinoshita H; Matsuda T; Yamada Y; Yamamoto S; Hirama H; Sugimoto M; Kakehi Y; Sakurai T; Tsuchiya N
BMC Cancer; 2019 Feb; 19(1):156. PubMed ID: 30770773
[TBL] [Abstract][Full Text] [Related]
20. Personalized peptide vaccination as second-line treatment for metastatic upper tract urothelial carcinoma.
Suekane S; Ueda K; Nishihara K; Sasada T; Yamashita T; Koga N; Yutani S; Shichijo S; Itoh K; Igawa T; Noguchi M
Cancer Sci; 2017 Dec; 108(12):2430-2437. PubMed ID: 28940789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
